| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 118 | 2023 | 5317 | 9.430 |
Why?
|
| Proto-Oncogene Proteins B-raf | 39 | 2022 | 1283 | 4.570 |
Why?
|
| Skin Neoplasms | 46 | 2022 | 4654 | 3.550 |
Why?
|
| Brain Neoplasms | 21 | 2023 | 4849 | 1.940 |
Why?
|
| Oximes | 7 | 2018 | 175 | 1.580 |
Why?
|
| Mutation | 55 | 2021 | 15179 | 1.540 |
Why?
|
| PTEN Phosphohydrolase | 16 | 2023 | 986 | 1.520 |
Why?
|
| Immunotherapy | 20 | 2023 | 3341 | 1.470 |
Why?
|
| Phosphatidylinositol 3-Kinases | 13 | 2016 | 1678 | 1.310 |
Why?
|
| Molecular Targeted Therapy | 11 | 2022 | 2330 | 1.240 |
Why?
|
| Imidazoles | 7 | 2018 | 999 | 1.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 14 | 2015 | 2054 | 1.120 |
Why?
|
| Genes, ras | 4 | 2013 | 667 | 1.110 |
Why?
|
| Antineoplastic Agents | 22 | 2020 | 14289 | 0.920 |
Why?
|
| Pyrimidinones | 5 | 2018 | 314 | 0.860 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2020 | 5178 | 0.850 |
Why?
|
| GTP Phosphohydrolases | 6 | 2018 | 336 | 0.840 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2016 | 639 | 0.820 |
Why?
|
| Pyridones | 5 | 2018 | 348 | 0.820 |
Why?
|
| Proto-Oncogene Proteins c-kit | 5 | 2014 | 479 | 0.820 |
Why?
|
| Protein Kinase Inhibitors | 15 | 2022 | 4757 | 0.800 |
Why?
|
| Humans | 158 | 2023 | 261506 | 0.780 |
Why?
|
| Benzimidazoles | 4 | 2019 | 428 | 0.770 |
Why?
|
| Signal Transduction | 25 | 2018 | 11965 | 0.760 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 299 | 0.740 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 1350 | 0.720 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 9 | 2022 | 992 | 0.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 15862 | 0.650 |
Why?
|
| Neoplasm Metastasis | 12 | 2020 | 5112 | 0.640 |
Why?
|
| Ipilimumab | 7 | 2023 | 710 | 0.610 |
Why?
|
| Biomarkers, Tumor | 16 | 2020 | 10331 | 0.610 |
Why?
|
| Proteomics | 6 | 2023 | 1380 | 0.590 |
Why?
|
| Neoplasms | 20 | 2022 | 15193 | 0.580 |
Why?
|
| Body Mass Index | 4 | 2023 | 2203 | 0.580 |
Why?
|
| Oxidative Phosphorylation | 4 | 2020 | 253 | 0.570 |
Why?
|
| Indoles | 6 | 2015 | 1009 | 0.570 |
Why?
|
| Phosphoric Monoester Hydrolases | 4 | 2002 | 243 | 0.560 |
Why?
|
| MAP Kinase Signaling System | 5 | 2016 | 848 | 0.550 |
Why?
|
| Point Mutation | 3 | 2013 | 769 | 0.540 |
Why?
|
| Azetidines | 1 | 2015 | 87 | 0.530 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2021 | 1048 | 0.530 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2016 | 2291 | 0.520 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 502 | 0.520 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2019 | 1249 | 0.510 |
Why?
|
| Interleukin-2 | 4 | 2014 | 842 | 0.510 |
Why?
|
| Cell Line, Tumor | 29 | 2021 | 14551 | 0.500 |
Why?
|
| Piperidines | 2 | 2019 | 1035 | 0.490 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2016 | 1823 | 0.490 |
Why?
|
| CTLA-4 Antigen | 7 | 2021 | 657 | 0.490 |
Why?
|
| Sulfonamides | 7 | 2019 | 1823 | 0.470 |
Why?
|
| Membrane Proteins | 6 | 2018 | 2819 | 0.460 |
Why?
|
| Tumor Microenvironment | 7 | 2022 | 2864 | 0.450 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 395 | 0.420 |
Why?
|
| Intracranial Hemorrhages | 1 | 2012 | 121 | 0.400 |
Why?
|
| Apoptosis | 12 | 2014 | 7591 | 0.400 |
Why?
|
| DNA Mutational Analysis | 8 | 2016 | 2283 | 0.390 |
Why?
|
| Neoplasm Staging | 19 | 2022 | 13658 | 0.390 |
Why?
|
| Middle Aged | 47 | 2023 | 86204 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 1546 | 0.380 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2011 | 146 | 0.380 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 528 | 0.370 |
Why?
|
| Protein Array Analysis | 7 | 2021 | 501 | 0.370 |
Why?
|
| Melanoma, Experimental | 4 | 2021 | 368 | 0.360 |
Why?
|
| Benzamides | 2 | 2012 | 1832 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 8873 | 0.360 |
Why?
|
| Male | 53 | 2023 | 123000 | 0.350 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 332 | 0.350 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2023 | 907 | 0.340 |
Why?
|
| Female | 57 | 2022 | 141928 | 0.340 |
Why?
|
| DNA Copy Number Variations | 7 | 2023 | 1516 | 0.330 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 11538 | 0.330 |
Why?
|
| Thiazoles | 2 | 2011 | 726 | 0.330 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2016 | 854 | 0.330 |
Why?
|
| Prognosis | 15 | 2023 | 21713 | 0.320 |
Why?
|
| Clinical Trials as Topic | 7 | 2021 | 3719 | 0.320 |
Why?
|
| Aged, 80 and over | 21 | 2021 | 29902 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2022 | 371 | 0.320 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 566 | 0.310 |
Why?
|
| T-Lymphocytes | 8 | 2021 | 3869 | 0.310 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2022 | 1763 | 0.310 |
Why?
|
| Adult | 34 | 2021 | 77950 | 0.310 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 335 | 0.310 |
Why?
|
| Animals | 31 | 2022 | 59536 | 0.310 |
Why?
|
| Aged | 31 | 2021 | 70117 | 0.300 |
Why?
|
| Obesity | 3 | 2023 | 2884 | 0.300 |
Why?
|
| Sentinel Lymph Node | 2 | 2021 | 216 | 0.290 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 3230 | 0.290 |
Why?
|
| Anticoagulants | 1 | 2012 | 787 | 0.280 |
Why?
|
| Genomics | 5 | 2022 | 2738 | 0.270 |
Why?
|
| Cancer Vaccines | 2 | 2021 | 697 | 0.270 |
Why?
|
| Leukemia | 1 | 2014 | 1635 | 0.260 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.260 |
Why?
|
| Meningeal Neoplasms | 2 | 2020 | 441 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3981 | 0.250 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2023 | 1064 | 0.250 |
Why?
|
| Disease-Free Survival | 12 | 2022 | 10001 | 0.250 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2018 | 521 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 4 | 2022 | 4975 | 0.240 |
Why?
|
| Risk Assessment | 5 | 2020 | 6869 | 0.230 |
Why?
|
| Immunohistochemistry | 8 | 2020 | 7548 | 0.230 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2016 | 261 | 0.230 |
Why?
|
| Lymphatic Metastasis | 4 | 2020 | 4844 | 0.230 |
Why?
|
| Survival Analysis | 8 | 2022 | 9180 | 0.220 |
Why?
|
| Transfection | 3 | 2010 | 2944 | 0.220 |
Why?
|
| Cohort Studies | 8 | 2021 | 9244 | 0.220 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 669 | 0.210 |
Why?
|
| Protein Kinases | 1 | 2006 | 874 | 0.210 |
Why?
|
| Cell Proliferation | 12 | 2020 | 7226 | 0.210 |
Why?
|
| Treatment Outcome | 14 | 2023 | 32848 | 0.200 |
Why?
|
| Phenylurea Compounds | 3 | 2015 | 580 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 4367 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 9 | 2019 | 5395 | 0.200 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 112 | 0.200 |
Why?
|
| Dietary Fiber | 1 | 2021 | 123 | 0.200 |
Why?
|
| Cell Survival | 8 | 2021 | 3045 | 0.200 |
Why?
|
| Mice | 22 | 2022 | 34495 | 0.200 |
Why?
|
| Arthritis | 1 | 2022 | 139 | 0.200 |
Why?
|
| Risk Factors | 7 | 2023 | 17523 | 0.190 |
Why?
|
| Jaw Diseases | 1 | 2020 | 21 | 0.190 |
Why?
|
| DNA Fingerprinting | 1 | 2021 | 167 | 0.190 |
Why?
|
| Pyrimidines | 2 | 2011 | 3518 | 0.190 |
Why?
|
| Gene Expression Profiling | 6 | 2020 | 5159 | 0.190 |
Why?
|
| RNA-Binding Proteins | 2 | 2018 | 984 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2020 | 53 | 0.180 |
Why?
|
| Tissue Array Analysis | 2 | 2020 | 760 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 264 | 0.180 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 117 | 0.180 |
Why?
|
| RNA, Small Interfering | 8 | 2014 | 2216 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.180 |
Why?
|
| Tumor Hypoxia | 1 | 2019 | 24 | 0.180 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 33 | 0.180 |
Why?
|
| Protein Interaction Maps | 1 | 2020 | 149 | 0.180 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 62 | 0.180 |
Why?
|
| Cell Division | 3 | 2002 | 2489 | 0.180 |
Why?
|
| Enzyme Inhibitors | 6 | 2014 | 1879 | 0.180 |
Why?
|
| Australia | 1 | 2020 | 225 | 0.170 |
Why?
|
| Oxadiazoles | 1 | 2019 | 57 | 0.170 |
Why?
|
| Receptors, OX40 | 1 | 2019 | 50 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 101 | 0.170 |
Why?
|
| Adenoviridae | 2 | 2002 | 1459 | 0.170 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 460 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
| Probiotics | 1 | 2021 | 228 | 0.170 |
Why?
|
| Arabidopsis Proteins | 1 | 1999 | 82 | 0.170 |
Why?
|
| Retrospective Studies | 13 | 2023 | 37905 | 0.160 |
Why?
|
| Myasthenia Gravis | 1 | 2019 | 99 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2021 | 349 | 0.160 |
Why?
|
| Plant Proteins | 1 | 1999 | 133 | 0.160 |
Why?
|
| Enterocolitis | 1 | 2018 | 43 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 1910 | 0.160 |
Why?
|
| Standard of Care | 2 | 2018 | 243 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 607 | 0.160 |
Why?
|
| Infliximab | 1 | 2018 | 130 | 0.160 |
Why?
|
| Potassium Channels | 1 | 1999 | 162 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 108 | 0.160 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 703 | 0.160 |
Why?
|
| Erythema Nodosum | 1 | 2017 | 15 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2021 | 351 | 0.160 |
Why?
|
| Blotting, Western | 5 | 2013 | 3536 | 0.160 |
Why?
|
| Protective Factors | 1 | 2018 | 106 | 0.160 |
Why?
|
| RNA | 1 | 2023 | 1013 | 0.160 |
Why?
|
| HLA-A Antigens | 1 | 2018 | 102 | 0.150 |
Why?
|
| Base Sequence | 6 | 2021 | 4917 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 131 | 0.150 |
Why?
|
| Panniculitis | 1 | 2017 | 58 | 0.150 |
Why?
|
| Adolescent | 8 | 2021 | 31252 | 0.150 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2014 | 107 | 0.140 |
Why?
|
| United States | 6 | 2021 | 15433 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2020 | 2450 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 878 | 0.140 |
Why?
|
| Pathology Department, Hospital | 1 | 2016 | 14 | 0.140 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 300 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2017 | 6150 | 0.140 |
Why?
|
| Headache | 1 | 2017 | 163 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10035 | 0.140 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2016 | 47 | 0.140 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2016 | 65 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 447 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2016 | 3552 | 0.130 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2016 | 99 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 1586 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 31 | 0.130 |
Why?
|
| Prostatic Neoplasms | 3 | 2002 | 5767 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2017 | 256 | 0.130 |
Why?
|
| Neuregulin-1 | 1 | 2015 | 83 | 0.130 |
Why?
|
| Incidence | 3 | 2021 | 5673 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 182 | 0.130 |
Why?
|
| Genetic Testing | 2 | 2015 | 1589 | 0.130 |
Why?
|
| Glycolysis | 1 | 2018 | 519 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 411 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 544 | 0.130 |
Why?
|
| Receptor, ErbB-3 | 1 | 2015 | 122 | 0.130 |
Why?
|
| Oncogenes | 2 | 2016 | 673 | 0.130 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2014 | 42 | 0.130 |
Why?
|
| DNA Primers | 3 | 2013 | 1399 | 0.130 |
Why?
|
| Quinolines | 2 | 2015 | 383 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1085 | 0.130 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 68 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.120 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 236 | 0.120 |
Why?
|
| Pyridines | 2 | 2012 | 1244 | 0.120 |
Why?
|
| Metalloproteins | 1 | 2014 | 26 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 577 | 0.120 |
Why?
|
| raf Kinases | 1 | 2014 | 81 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 4298 | 0.120 |
Why?
|
| Fever | 1 | 2017 | 497 | 0.120 |
Why?
|
| Antigen Presentation | 1 | 2015 | 272 | 0.120 |
Why?
|
| 5' Untranslated Regions | 1 | 2014 | 93 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 235 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2016 | 247 | 0.120 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 135 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2013 | 19 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2001 | 2488 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1294 | 0.120 |
Why?
|
| Ribosomal Proteins | 1 | 2014 | 118 | 0.120 |
Why?
|
| Smad4 Protein | 1 | 2015 | 196 | 0.120 |
Why?
|
| Exons | 3 | 2012 | 1328 | 0.120 |
Why?
|
| Phosphorylation | 7 | 2018 | 4804 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5319 | 0.120 |
Why?
|
| Gonanes | 1 | 2013 | 45 | 0.120 |
Why?
|
| Taxoids | 2 | 2016 | 967 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 527 | 0.120 |
Why?
|
| Genetic Loci | 1 | 2016 | 481 | 0.120 |
Why?
|
| Thioredoxins | 1 | 2013 | 50 | 0.110 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 265 | 0.110 |
Why?
|
| Niacinamide | 2 | 2012 | 421 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 1081 | 0.110 |
Why?
|
| Uveal Neoplasms | 2 | 2012 | 176 | 0.110 |
Why?
|
| Quality Control | 1 | 2014 | 457 | 0.110 |
Why?
|
| Models, Genetic | 2 | 2014 | 1113 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2015 | 253 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 2483 | 0.110 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2012 | 47 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2017 | 5270 | 0.110 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 362 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 6942 | 0.110 |
Why?
|
| Mice, Nude | 5 | 2019 | 4307 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2012 | 34 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 137 | 0.110 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 204 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 838 | 0.110 |
Why?
|
| Disease Progression | 6 | 2023 | 6682 | 0.110 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 56 | 0.110 |
Why?
|
| Lymphangiogenesis | 1 | 2012 | 46 | 0.100 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2012 | 37 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2016 | 1053 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 67 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2022 | 1048 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2023 | 12873 | 0.100 |
Why?
|
| Patient Selection | 2 | 2019 | 2055 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 1493 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2012 | 147 | 0.100 |
Why?
|
| Biomarkers | 3 | 2019 | 5047 | 0.100 |
Why?
|
| Tyrphostins | 1 | 2011 | 107 | 0.100 |
Why?
|
| Glioblastoma | 2 | 2019 | 1797 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 7789 | 0.100 |
Why?
|
| Phosphotransferases | 1 | 2011 | 84 | 0.100 |
Why?
|
| Metalloproteases | 1 | 2010 | 24 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 195 | 0.100 |
Why?
|
| Hepatic Insufficiency | 1 | 2010 | 34 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 691 | 0.100 |
Why?
|
| Brain | 2 | 2014 | 4113 | 0.100 |
Why?
|
| Mutagenesis | 1 | 2012 | 483 | 0.100 |
Why?
|
| Phosphatidic Acids | 1 | 2010 | 16 | 0.100 |
Why?
|
| Genotype | 2 | 2017 | 4109 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 3639 | 0.090 |
Why?
|
| Extremities | 1 | 2012 | 303 | 0.090 |
Why?
|
| Protein Binding | 5 | 2018 | 3438 | 0.090 |
Why?
|
| Time Factors | 3 | 2021 | 12926 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2012 | 1016 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2010 | 86 | 0.090 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 8865 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 238 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2016 | 1439 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2012 | 575 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2010 | 134 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2015 | 1442 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 622 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2012 | 519 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2594 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1026 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2013 | 549 | 0.090 |
Why?
|
| Dasatinib | 2 | 2011 | 862 | 0.090 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 211 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2020 | 2967 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2011 | 1163 | 0.080 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 3343 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 419 | 0.080 |
Why?
|
| Nevus, Pigmented | 1 | 2009 | 104 | 0.080 |
Why?
|
| Biopsy | 4 | 2019 | 3443 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 259 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 1331 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6207 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2012 | 1732 | 0.080 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 1519 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2011 | 478 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3251 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 3821 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 488 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2021 | 756 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.080 |
Why?
|
| Lysine | 1 | 2010 | 422 | 0.080 |
Why?
|
| Gene Expression | 4 | 2018 | 3570 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2022 | 1415 | 0.080 |
Why?
|
| Autophagy | 1 | 2014 | 927 | 0.080 |
Why?
|
| Carcinoma | 1 | 1999 | 2578 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2326 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2015 | 1154 | 0.080 |
Why?
|
| Sirolimus | 1 | 2012 | 814 | 0.080 |
Why?
|
| Software | 1 | 2014 | 1321 | 0.080 |
Why?
|
| Clone Cells | 2 | 2020 | 555 | 0.070 |
Why?
|
| Algorithms | 2 | 2016 | 3890 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 2265 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2012 | 3976 | 0.070 |
Why?
|
| Cisplatin | 2 | 2014 | 2432 | 0.070 |
Why?
|
| Vincristine | 1 | 2010 | 1511 | 0.070 |
Why?
|
| ErbB Receptors | 3 | 2021 | 2295 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2015 | 1290 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 852 | 0.070 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 7222 | 0.070 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2019 | 190 | 0.070 |
Why?
|
| B7-H1 Antigen | 3 | 2017 | 1022 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2518 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 4821 | 0.070 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 6089 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 1665 | 0.060 |
Why?
|
| Genome, Human | 1 | 2013 | 1869 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 1121 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 1390 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2015 | 4549 | 0.060 |
Why?
|
| Exome | 3 | 2016 | 1239 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3001 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 4892 | 0.060 |
Why?
|
| Enzyme Activation | 3 | 2009 | 1764 | 0.060 |
Why?
|
| Lymph Node Excision | 2 | 2022 | 1959 | 0.060 |
Why?
|
| Dacarbazine | 2 | 2016 | 485 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2009 | 1152 | 0.060 |
Why?
|
| Gene Dosage | 2 | 2017 | 829 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2012 | 5637 | 0.060 |
Why?
|
| Survival Rate | 3 | 2022 | 12221 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 3260 | 0.060 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 139 | 0.050 |
Why?
|
| Computational Biology | 2 | 2020 | 1271 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 3203 | 0.050 |
Why?
|
| Phosphotyrosine | 1 | 2002 | 111 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2012 | 2084 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2021 | 1869 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4053 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 448 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 4988 | 0.050 |
Why?
|
| Melanocytes | 2 | 2012 | 219 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 105 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 2 | 2012 | 80 | 0.050 |
Why?
|
| Morpholines | 2 | 2015 | 289 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2013 | 1694 | 0.050 |
Why?
|
| Anal Canal | 1 | 2022 | 238 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 149 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7702 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 160 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 269 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 4938 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 34 | 0.050 |
Why?
|
| Piperazines | 1 | 2009 | 2101 | 0.050 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 38 | 0.050 |
Why?
|
| Organ Sparing Treatments | 1 | 2022 | 277 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2021 | 266 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2015 | 1313 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 77 | 0.040 |
Why?
|
| Cell Movement | 3 | 2012 | 2466 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2019 | 289 | 0.040 |
Why?
|
| Cytokines | 2 | 2015 | 2809 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2019 | 100 | 0.040 |
Why?
|
| Cell Membrane | 2 | 2015 | 850 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2013 | 1489 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 286 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2016 | 1987 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 6295 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2019 | 238 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 1062 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 770 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2018 | 53 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 649 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 309 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2018 | 105 | 0.040 |
Why?
|
| Suppression, Genetic | 1 | 2017 | 67 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1165 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 702 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 129 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 198 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 98 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 733 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2315 | 0.040 |
Why?
|
| Ribosomal Protein S6 | 1 | 2016 | 46 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2018 | 343 | 0.040 |
Why?
|
| Transgenes | 1 | 1998 | 557 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2016 | 61 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 14889 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2016 | 162 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 170 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 344 | 0.030 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2016 | 34 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 675 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 798 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5061 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 259 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2016 | 81 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 4233 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 651 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 754 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 280 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2015 | 257 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 109 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 1616 | 0.030 |
Why?
|
| Nitrosation | 1 | 2014 | 10 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 400 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 218 | 0.030 |
Why?
|
| Freezing | 1 | 2014 | 59 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 1301 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 212 | 0.030 |
Why?
|
| Drug Approval | 1 | 2015 | 178 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 280 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 833 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2018 | 1144 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 242 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2015 | 2074 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 6100 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2015 | 209 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 332 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4557 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2014 | 105 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 1756 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 598 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2013 | 142 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 226 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 588 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 829 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 672 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 582 | 0.030 |
Why?
|
| Lentivirus | 1 | 2013 | 169 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 240 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 734 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 1183 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2016 | 745 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2012 | 52 | 0.030 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 138 | 0.030 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2013 | 145 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 591 | 0.030 |
Why?
|
| Administration, Metronomic | 1 | 2011 | 15 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2012 | 223 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 142 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 1544 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 597 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 973 | 0.020 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2010 | 15 | 0.020 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 476 | 0.020 |
Why?
|
| ADAMTS Proteins | 1 | 2010 | 15 | 0.020 |
Why?
|
| Sulfones | 1 | 2012 | 143 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2013 | 576 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2012 | 143 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 65 | 0.020 |
Why?
|
| Phosphodiesterase I | 1 | 2010 | 20 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 231 | 0.020 |
Why?
|
| Half-Life | 1 | 2010 | 259 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 875 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1681 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 844 | 0.020 |
Why?
|
| Pyrophosphatases | 1 | 2010 | 51 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2010 | 103 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 342 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2014 | 889 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2014 | 1090 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 671 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 644 | 0.020 |
Why?
|
| Threonine | 1 | 2010 | 161 | 0.020 |
Why?
|
| Ascites | 1 | 2010 | 198 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3890 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 1046 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2292 | 0.020 |
Why?
|
| Pyridazines | 1 | 2012 | 293 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 803 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 997 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1085 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 505 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2011 | 309 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2010 | 213 | 0.020 |
Why?
|
| Chromones | 1 | 2009 | 120 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 837 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 324 | 0.020 |
Why?
|
| Melphalan | 1 | 2012 | 834 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 2173 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.020 |
Why?
|
| Liposomes | 1 | 2010 | 684 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1152 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 810 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 1248 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 694 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 1914 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1399 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2010 | 459 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 905 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 886 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1408 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 673 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Azacitidine | 1 | 2012 | 1149 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 1643 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1533 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 4971 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3569 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 1506 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 891 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3101 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 1549 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 15694 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2002 | 81 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 392 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2002 | 303 | 0.010 |
Why?
|
| Androstadienes | 1 | 2001 | 165 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 2045 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2013 | 2947 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 2049 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1999 | 196 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 1487 | 0.010 |
Why?
|
| Epidermis | 1 | 1999 | 188 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 367 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1999 | 241 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 2171 | 0.010 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1999 | 272 | 0.010 |
Why?
|
| Child | 1 | 2016 | 29154 | 0.010 |
Why?
|
| Glioma | 1 | 2002 | 1963 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 5437 | 0.000 |
Why?
|